Dr Parag Gajendragadkar
MA, MBBChir, MPhil (Cantab), DPhil (Oxon), MRCP
Senior Clinical Research Fellow
Parag Gajendragadkar was appointed to Oxford Population Health in 2023 following a DPhil here with interests in genetic epidemiology and mechanistic clinical trials involving cardiovascular arrhythmias such as atrial fibrillation. He combines this with working as a consultant cardiologist at Royal Papworth Hospital in Cambridge where he specialises in clinical electrophysiology and devices, diagnosing and performing procedures to treat patients with cardiac rhythm disorders.
He studied medicine at the University of Cambridge with a number of prizes and distinctions across both undergraduate and clinical medical studies. He was a Wellcome funded academic clinical fellow and completed an MPhil in translational medicine and therapeutics there, focussing on translating promising drug compounds into early human studies.
After commencing cardiology specialist training within the East of England in 2012, he focussed on electrophysiology and devices and moved to Oxford as a BHF clinical research fellow, and was awarded a DPhil which encompassed both basic science and animal work in the Radcliffe Department of Medicine as well as genetic epidemiology within the Big Data Institute and Oxford Population Health (supervisors Prof Barbara Casadei, Dr Jillian Simon, Prof Jemma Hopewell). For the work within Oxford Population Health, he was awarded the European Society of Cardiology Young Investigator Award for Population Sciences in 2019.
Independent effects of adiposity measures on risk of atrial fibrillation in men and women: a study of 0.5 million individuals.
Camm CF. et al, (2022), Int J Epidemiol, 51, 984 - 995
Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.
Mäki-Petäjä KM. et al, (2021), Hypertension, 77, 1591 - 1599
Assessment of the causal relevance of ECG parameters for risk of atrial fibrillation: A mendelian randomisation study.
Gajendragadkar PR. et al, (2021), PLoS Med, 18
Oxidation of Protein Kinase A Regulatory Subunit PKARIα Protects Against Myocardial Ischemia-Reperfusion Injury by Inhibiting Lysosomal-Triggered Calcium Release.
Simon JN. et al, (2021), Circulation, 143, 449 - 465
Admission of patients with STEMI since the outbreak of the COVID-19 pandemic: a survey by the European Society of Cardiology.
Pessoa-Amorim G. et al, (2020), Eur Heart J Qual Care Clin Outcomes, 6, 210 - 216